This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Results of a Two-Year Controlled Study

Gerard E. Hogarty, MSW; Joseph P. McEvoy, MD; Mark Munetz, MD; Ann Louise DiBarry, MSN; Patricia Bartone, MSN; Rosemary Cather, MSN; Susan J. Cooley, MNEd; Richard F. Ulrich, MS; Mary Carter, PhD; Michael J. Madonia, MSW

Arch Gen Psychiatry. 1988;45(9):797-805.

Abstract
• Issues regarding the side effects of antipsychotic medication and the possible contribution of the environment to dose requirements led to a two-year controlled dosage study of maintenance antipsychotic medication and familial environment among recently discharged schizophrenic patients. Seventy stable patients, living in high— or low—expressed emotion (EE) households, were randomized, double blind, to receive a standard dose of fluphenazine decanoate (average, 25 mg every two weeks) or a minimal dose representing 20% of the dose prescribed (average, 3.8 mg every two weeks). No differences in relapse were observed among dose, EE, or dose and EE. Patients in the minimal dose/high-EE condition experienced more minor but aborted episodes in year 2. Side effects were fewer on the minimal dose after one year, and low-EE patients were better adjusted than high-EE patients. Over time, minimal-dose recipients were significantly more improved in their instrumental and interpersonal role performance than were standard-dose recipients.

Author Affiliations
From the Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine. Dr Munetz is now with the Department of Psychiatry, University of Massachusetts, Worcester.

Footnotes
Accepted for publication Oct 23, 1987.

Reprint requests to Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, 3811O'Hara St, Pittsburgh, PA 15213-2593 (Mr Hogarty).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Gerard E. Hogarty (1935 2006): Combining Science and Humanism to Improve the Care of Persons With Schizophrenia
Eack et al.
Schizophr Bull 2007;33:1056-1062.
ABSTRACT | FULL TEXT  

Cognitive Enhancement Therapy for Schizophrenia: Effects of a 2-Year Randomized Trial on Cognition and Behavior
Hogarty et al.
Arch Gen Psychiatry 2004;61:866-876.
ABSTRACT | FULL TEXT  

Three-Year Trials of Personal Therapy Among Schizophrenic Patients Living With or Independent of Family, I: Description of Study and Effects on Relapse Rates
Hogarty et al.
Focus 2004;2:146-157.
ABSTRACT | FULL TEXT  

Maintenance Medication for Schizophrenia: Strategies for Dose Reduction
Schooler
Focus 2004;2:175-186.
ABSTRACT | FULL TEXT  

Integration of Care: Integrated Treatment of Schizophrenia
Lenroot et al.
Psychiatr. Serv. 2003;54:1499-1507.
ABSTRACT | FULL TEXT  

Antipsychotic Dosage at Hospital Discharge and Outcomes Among Persons With Schizophrenia
Sohler et al.
Psychiatr. Serv. 2003;54:1258-1263.
ABSTRACT | FULL TEXT  

A Multidose Study of Haloperidol Decanoate in the Maintenance Treatment of Schizophrenia
Kane et al.
Am. J. Psychiatry 2002;159:554-560.
ABSTRACT | FULL TEXT  

Comparative Effectiveness of Fluphenazine Decanoate Injections Every 2 Weeks Versus Every 6 Weeks
Carpenter et al.
Am. J. Psychiatry 1999;156:412-418.
ABSTRACT | FULL TEXT  

Three-Year Trials of Personal Therapy Among Schizophrenic Patients Living With or Independent of Family, I: Description of Study and Effects on Relapse Rates
Hogarty et al.
Am. J. Psychiatry 1997;154:1504-1513.
ABSTRACT | FULL TEXT  

Relapse and Rehospitalization During Maintenance Treatment of Schizophrenia: The Effects of Dose Reduction and Family Treatment
Schooler et al.
Arch Gen Psychiatry 1997;54:453-463.
ABSTRACT  

The Influence of Expressed Emotion, Family Dynamics, and Symptom Type on the Social Adjustment of Schizophrenic Young Adults
King and Dixon
Arch Gen Psychiatry 1996;53:1098-1104.
ABSTRACT  

Schizophrenia
Kane
NEJM 1996;334:34-42.
FULL TEXT  

Psychopharmacology, Ethnicity and Culture
Lin et al.
Transcultural Psychiatry 1995;32:3-40.
 

Pharmacotherapy of Impaired Affect in Recovering Schizophrenic Patients
Hogarty et al.
Arch Gen Psychiatry 1995;52:29-41.
ABSTRACT  

Fluphenazine vs Placebo Supplementation for Prodromal Signs of Relapse in Schizophrenia
Marder et al.
Arch Gen Psychiatry 1994;51:280-287.
ABSTRACT  

Progress in Psychiatry- First of Two Parts
Michels and Marzuk
NEJM 1993;329:552-560.
FULL TEXT  

Optimal Dose of Neuroleptic in Acute Schizophrenia: A Controlled Study of the Neuroleptic Threshold and Higher Haloperidol Dose
McEvoy et al.
Arch Gen Psychiatry 1991;48:739-745.
ABSTRACT  

Intermittent vs Maintenance Medication in Schizophrenia: Two-Year Results
Herz et al.
Arch Gen Psychiatry 1991;48:333-339.
ABSTRACT  

Family Psychoeducation, Social Skills Training, and Maintenance Chemotherapy in the Aftercare Treatment of Schizophrenia: II. Two-Year Effects of a Controlled Study on Relapse and Adjustment
Hogarty et al.
Arch Gen Psychiatry 1991;48:340-347.
ABSTRACT  

Social Work Practice Research on Severe Mental Illness: Charting a Future
Hogarty
Research on Social Work Practice 1991;1:5-31.
ABSTRACT  

A Controlled Dose Comparison of Haloperidol in Newly Admitted Schizophrenic Patients
Van Putten et al.
Arch Gen Psychiatry 1990;47:754-758.
ABSTRACT  

Fluphenazine Dose, Clinical Response, and Extrapyramidal Symptoms During Acute Treatment
Levinson et al.
Arch Gen Psychiatry 1990;47:761-768.
ABSTRACT